Lexicon Pharmaceuticals (LXRX)
(Delayed Data from NSDQ)
$1.22 USD
+0.13 (11.93%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $1.23 +0.01 (0.82%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Lexicon Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
LXRX 1.22 +0.13(11.93%)
Will LXRX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for LXRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXRX
Lexicon (LXRX) Upgraded to Buy: Here's What You Should Know
Lexicon Pharmaceuticals (LXRX) Q2 Earnings and Revenues Top Estimates
LXRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Supernus Pharmaceuticals (SUPN) Surpasses Q2 Earnings and Revenue Estimates
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
KURA Stock Rises More Than 15% This Past Week: Here's Why
Other News for LXRX
MACD Bearish Centerline Cross appears for LXRX after 0.91% move
Lexicon Pharmaceuticals: Promising Phase 2b Results for Pilavapadin Support Buy Rating
20 Day Moving Average Resistance appears for LXRX after 1.79% move
Lexicon Pharmaceuticals (LXRX) Highlights Promising Phase 2b Study Results
Lexicon announces presents data from Phase 2 PROGRESS study for pilavapadin